City Therapeutics, Inc.

City Therapeutics is a biopharmaceutical company that develops RNA interference (RNAi)-based medicines. The company engineers RNAi trigger molecules, specifically small interfering RNAs (siRNAs), to build a pipeline of therapeutics. These therapeutics target diseases across multiple areas, including ophthalmologic conditions such as retinal diseases and geographic atrophy. City Therapeutics designs and engineers RNAi trigger molecules with features like smaller size, novel cleavage mechanisms, and tailored targeting ligands to improve potency, specificity, and delivery to various tissue types. Its product pipeline includes CITY-FXI, a city-engineered n-acetylgalactosamine-conjugated small interfering RNA therapeutic targeting factor XI. Another product is CITY-RBP4, a city-engineered GalNAc-conjugated siRNA therapeutic in development for the treatment of Stargardt disease. Additionally, CITY-TFR2 is a city-engineered GalNAc-conjugated siRNA therapeutic candidate in development for anemia of chronic disease. The company advances these therapeutics from research through clinical and commercial development. City Therapeutics also engages in strategic collaborations to co-develop RNAi clinical candidates, including partnerships with Bausch + Lomb Ireland Limited and Biogen MA Inc. to advance extrahepatic RNAi therapeutics for diseases of the eye and the central nervous system. The company serves clients in the pharmaceutical, biotechnology, and life sciences industries and collaborates with organizations in the ophthalmology sector. City Therapeutics was incorporated in 2023 and is based in Cambridge, Massachusetts.